|
|||||
|
|
Avoid Delivering Therapies for Nonsustained Fast Ventricular Tachyarrhythmia in Patients with Implantable Cardioverter/Defibrillator: The ADVANCE III Trial |
|
| Authors: | JOERG O. SCHWAB,M.D.,F.E.S.C.,MAURIZIO GASPARINI,M.D.,&dagger ,MAURIZIO LUNATI,M.D.,&Dagger ,ALESSANDRO PROCLEMER,M.D.,§ ,BERND KAUP¶ ,ELISABETTA SANTI,M.D.,,GUISEPPE LIGORIO,CATHERINE KLERSY,M.D.,M.Sc.,&dagger &dagger ,JOÃ O DE SOUSA,M.D.,&Dagger &Dagger ,RZEJ OKREGLICKI,M.D.,Professor,§ § ,ANGEL ARENAL,M.D.,¶ ¶ ,MAURITS WIJFFELS,M.D.,, BERND LEMKE,M.D.,&dagger &dagger &dagger |
| Affiliation: | From the Department of Medicine-Cardiology, University of Bonn, Bonn, Germany;;Istituto Clinico Humanitas, Milano, Italy;;Ospedale Niguarda, Milano, Italy;;Az. Osp. S. Maria della Misericordia, Udine, Italy;;Medtronic Duesseldorf, Germany;;Medtronic Italia S. p A, Italy;;Servizio di Biometria ed Epidemiologia Clinica Direzione Scientifica –Fondazione IRCCS Policlinico san Matteo, Pavia, Italy;;H. Santa Maria, Lisbon, Portugal;;University of Cape Town, Cape Town, South Africa;;Hospital G. Marañón, Madrid, Spain;;St. Antonius hospital, Nieuwegein, The Netherlands;;and Klinikum Luedenscheid, Luedenscheid, Germany |
| Abstract: | Introduction: The purpose of this investigation is to evaluate whether a prolonged detection interval for life threatening ventricular tachyarrhythmia (VT) is able to reduce therapies (Rx) delivered by an implantable cardioverter/defibrillator (ICD). Until now, only the PREPARE trial demonstrated a reduction of ICD Rx in a cohort of primary prevention patients. Methods and Results: The ADVANCE III study is a prospective, randomized, parallel trial with 2 arms evaluating different intervals to detect (NID), i.e., 18/24 (as currently used) versus 30/40. The primary endpoint is to demonstrate a 20% reduction of ICD Rx (antitachycardia pacing or shocks) delivered to terminate spontaneous VT with a cycle length ≤320 ms in patients with Class I-IIA indication for ICD therapy, regardless of cardiac resynchronization capabilities. The worldwide investigation started in spring 2008 and is expected to be finished in 2011. Conclusions: The ADVANCE III trial is the first randomized investigation evaluating the reduction of ICD Rx for fast VT due to a prolongation of NID in a general ICD patient cohort. |
| Keywords: | implantable cardioverter/defibrillator therapy detection interval prolongation ventricular tachyarrhythmia prospective randomized trial |